ES2629309T3 - Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora - Google Patents

Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora Download PDF

Info

Publication number
ES2629309T3
ES2629309T3 ES09700368.5T ES09700368T ES2629309T3 ES 2629309 T3 ES2629309 T3 ES 2629309T3 ES 09700368 T ES09700368 T ES 09700368T ES 2629309 T3 ES2629309 T3 ES 2629309T3
Authority
ES
Spain
Prior art keywords
treatment
formulations
antitumor
immunosuppressive therapy
mucositis induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09700368.5T
Other languages
English (en)
Inventor
Ezio Bombardelli
Gabriele Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Application granted granted Critical
Publication of ES2629309T3 publication Critical patent/ES2629309T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60S—SERVICING, CLEANING, REPAIRING, SUPPORTING, LIFTING, OR MANOEUVRING OF VEHICLES, NOT OTHERWISE PROVIDED FOR
    • B60S3/00—Vehicle cleaning apparatus not integral with vehicles
    • B60S3/04—Vehicle cleaning apparatus not integral with vehicles for exteriors of land vehicles
    • B60S3/06—Vehicle cleaning apparatus not integral with vehicles for exteriors of land vehicles with rotary bodies contacting the vehicle
    • B60S3/063—Vehicle cleaning apparatus not integral with vehicles for exteriors of land vehicles with rotary bodies contacting the vehicle the axis of rotation being approximately vertical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Formulaciones que contienen sanguinarina o queleritrina en forma de sales de ácido luteico en mezcla con vehículos y/o excipientes adecuados para su uso en el tratamiento y/o la prevención de la mucositis.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES09700368.5T 2008-01-11 2009-01-08 Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora Active ES2629309T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000038A ITMI20080038A1 (it) 2008-01-11 2008-01-11 Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva
ITMI20080038 2008-10-30
PCT/EP2009/000050 WO2009087091A2 (en) 2008-01-11 2009-01-08 Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy

Publications (1)

Publication Number Publication Date
ES2629309T3 true ES2629309T3 (es) 2017-08-08

Family

ID=40290063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09700368.5T Active ES2629309T3 (es) 2008-01-11 2009-01-08 Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora

Country Status (17)

Country Link
US (1) US8940338B2 (es)
EP (1) EP2231158B1 (es)
JP (1) JP5357896B2 (es)
KR (1) KR20100100953A (es)
CN (1) CN101917997A (es)
AU (1) AU2009203819B2 (es)
CA (1) CA2711840C (es)
DK (1) DK2231158T3 (es)
ES (1) ES2629309T3 (es)
HU (1) HUE035036T2 (es)
IL (1) IL206881A (es)
IT (1) ITMI20080038A1 (es)
PL (1) PL2231158T3 (es)
PT (1) PT2231158T (es)
RU (1) RU2460535C2 (es)
SI (1) SI2231158T1 (es)
WO (1) WO2009087091A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776464T3 (es) 2005-07-19 2020-07-30 Texas Enterosorbents Inc Conservante y aditivo para alimentos y piensos
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
AU2007277428B2 (en) 2006-06-27 2013-09-19 The Texas A & M University System Composition for the enterosorption and management of toxins comprising a calcium aluminosilicate clay
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
WO2013059827A1 (en) * 2011-10-20 2013-04-25 Salient Pharmaceuticals, Inc. Methods and compositions for treating mucositis
AT515336A1 (de) * 2014-02-03 2015-08-15 Roth Hermann Dr Vermeidung oxidativer Prozesse und oxidativem Stress
PT3661490T (pt) * 2017-07-31 2021-11-05 Mucosa Innovations S L Composição para utilização na prevenção e/ou tratamento de mucositite oral gastrointestinal induzida por tratamento oncológico

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254321B (it) * 1992-04-10 1995-09-14 Kemiprogress S R L Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
JP2000109428A (ja) * 1998-10-05 2000-04-18 Taisho Pharmaceut Co Ltd 咽頭粘膜用組成物
ITMI20042414A1 (it) * 2004-12-17 2005-03-17 Indena Spa Formulazione per il trattamento di affezioni delle prime vie respiratorie
US7491414B2 (en) * 2005-10-12 2009-02-17 Gaia Herbs, Inc. Anti-inflammatory substances extracted from Echinacea
EP1882473A1 (en) * 2006-07-28 2008-01-30 Indena S.P.A. Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono

Also Published As

Publication number Publication date
WO2009087091A8 (en) 2009-10-08
CA2711840C (en) 2014-02-18
PT2231158T (pt) 2017-07-03
CN101917997A (zh) 2010-12-15
WO2009087091A3 (en) 2009-11-26
US20100284945A1 (en) 2010-11-11
AU2009203819A1 (en) 2009-07-16
DK2231158T3 (en) 2017-06-12
WO2009087091A2 (en) 2009-07-16
EP2231158B1 (en) 2017-04-05
IL206881A0 (en) 2010-12-30
IL206881A (en) 2015-09-24
US8940338B2 (en) 2015-01-27
JP2011509270A (ja) 2011-03-24
HUE035036T2 (en) 2018-05-02
KR20100100953A (ko) 2010-09-15
AU2009203819B2 (en) 2014-07-31
RU2460535C2 (ru) 2012-09-10
ITMI20080038A1 (it) 2009-07-12
CA2711840A1 (en) 2009-07-16
EP2231158A2 (en) 2010-09-29
SI2231158T1 (sl) 2017-06-30
RU2010128171A (ru) 2012-01-20
PL2231158T3 (pl) 2017-09-29
JP5357896B2 (ja) 2013-12-04

Similar Documents

Publication Publication Date Title
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2478820T3 (es) Tratamiento de degeneración macular
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2505643T3 (es) Galectina para uso en el tratamiento del síndrome del ojo seco
ES2629749T3 (es) Inmunidad tumoral
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
ES2650463T3 (es) Tratamiento de enfermedades inflamatorias con ACE2
CR20170097A (es) Compuestos terapéuticamente activos y sus métodos de uso (divisional)
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
ES2527454T3 (es) El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
ES2528366T3 (es) Citicolina para el tratamiento del glaucoma
UY29417A1 (es) Agentes endoparasiticidas
CL2019003293A1 (es) Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores sólidos.
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
CL2011001258A1 (es) Sales de adicion de acido citrico de (r)-5-((e)-2-pirrolidin-3-il vinil)pirimidina; formas polimorficas monocitrato; composicion farmaceutica que las comprende; y su uso en la prevencion o en el tratamiento del dolor, inflamacion o un trastorno del sistema nervioso central.